Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson gets more time to complete Andrx takeover
The amendment of their merger agreement of March 12, 2006 sees the deadline to close the transaction extended from September 12, 2006 until November 13, 2006. The amendment
The amendment of their merger agreement of March 12, 2006 sees the deadline to close the transaction extended from September 12, 2006 until November 13, 2006. The amendment
As a result of a recent meeting with the FDA, the companies announced that they would re-submit an amended application seeking approval for RSD1235. Under terms of the
QS-21 is the leading member of the Stimulon family of adjuvants developed by Antigenics, and has been shown to stimulate both antibody as well as cellular immune responses.
Researchers at the UK’s Drug Safety Research Unit and University of Portsmouth analyzed prescribing data for 11,185 patients seen by NHS family doctors. The data was gathered from
The FDA granted final approval for the company’s azithromycin for oral suspension, a generic version of Pfizer’s antibiotic Zithromax, and warfarin sodium tablets, a generic version of Bristol-Myers
The team, led by Professor Seong-Seng Tan at Melbourne’s Howard Florey Institute, has discovered that this naturally occurring protein, called BP5, is produced more than usual in brain
Barr confirmed that J&J unit Janssen Pharmaceutica NV, the holder of the Razadyne new drug application, and Synaptech, the holder of the patent, had filed the suit against
The pivotal study will include approximately 162 non-Hodgkin’s lymphoma (NHL) patients who are refractory to rituximab in combination with chemotherapy or to rituximab given as maintenance treatment. “NHL
Under the agreement, Takeda has received exclusive worldwide rights to develop, manufacture and market the HuL2G7 antibody. Takeda will pay Galaxy an upfront licensing fee of $2 million,
These patients will be enrolled from approximately six clinical sites in the US and given interferon or placebo for four weeks to assess the effect of treatment on